- $14.53m
- $16.61m
- $2.29m
Brief: Femasys Inc Announces Commercial Availability Of Its Femcath Intrauterine Device
Brief: Femasys Enrollment Over 25% Complete For Femaseed De Novo Trial
Brief: Femasys Inc Provides Strategic Update On Its Femaseed Pivotal Trial Design
Femasys up on completing enrollment for birth control solution trial
Brief: Femasys Inc. Announces Enrollment Completion For Stage 2 Study Of Fembloc For Permanent Birth Control
Brief: Femasys Inc. Announces Financial Results For The Second Quarter Ended June 30, 2022 And Provides Corporate Update
Brief: Femasys Inc Announces Existing Board Member Charles Larsen As Chairperson Of Board
Brief: Femasys Inc - Files For Mixed Shelf Of Upto $150 Million - SEC Filing
U.S. abortion ruling ignites retail interest in women contraceptive makers - Vanda
Brief: Femasys Announces Financial Results For The First Quarter Ended March 31, 2022
JonesTrading cuts PT for Femasys on clinical trial delays
Wainwright cheers Femasys' infertility, birth control treatment
Brief: Femasys Announces Appointment Of Dov Elefant To CFO
Brief: Femasys Inc. Announces The Appointment Of Wendy Perrow, Transformational Biotech Entrepreneur, As New Board Member
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:43 AM
Brief: Femasys Reports Q3 2021 Financial Results
Brief: Femasys To Join Russell Microcap Index
Brief: Femasys Inc. Announces The Appointment Of Edward Evantash, M.D. As Chief Medical Officer
Brief: Femasys Posts Q2 Loss Per Share Of $0.52